Pyxis Oncology’s CEO to Speak at Stifel 2025 Virtual Targeted Oncology Forum
Boston, MA – April 2, 2025 – Pyxis Oncology, a clinical-stage biotech company specializing in the development of next-generation therapeutics for difficult-to-treat cancers, has announced that Lara S. Sullivan, M.D., the company’s President, CEO, and CMO, will participate in a fireside chat at the Stifel 2025 Virtual Targeted Oncology Forum. The event is scheduled for Wednesday, April 9, 2025, at 11:30 a.m. Eastern Time.
About Pyxis Oncology
Pyxis Oncology is a clinical-stage biotech company focused on the discovery, development, and commercialization of innovative therapies for various forms of cancer. The company’s pipeline includes several promising candidates, such as:
- PYXS-6128, a small molecule inhibitor of the EGFR family of receptors, currently in phase 1 clinical trials for the treatment of advanced solid tumors
- PYXS-6330, a CD47-targeted monoclonal antibody, in preclinical development for the treatment of various hematological malignancies
Impact on the Biotech Industry
Pyxis Oncology’s participation in the Stifel 2025 Virtual Targeted Oncology Forum signifies the company’s commitment to sharing its latest research findings and therapeutic developments with the investment community. This event is expected to provide valuable insights into the company’s pipeline and potential growth opportunities in the oncology sector.
Impact on Patients and the Medical Community
The advancements made by Pyxis Oncology and other pioneering biotech companies could lead to the development of more effective and targeted cancer treatments. The fireside chat and one-on-one investor meetings at the Stifel 2025 Virtual Targeted Oncology Forum represent an opportunity for the medical community and investors to engage with the company and learn more about its therapeutic candidates.
Conclusion
Pyxis Oncology’s upcoming appearance at the Stifel 2025 Virtual Targeted Oncology Forum is an exciting development for the biotech industry and the oncology community. The fireside chat and one-on-one investor meetings will provide valuable insights into the company’s pipeline, growth opportunities, and commitment to developing next-generation therapeutics for difficult-to-treat cancers. As a curious observer or potential investor, staying informed about these developments could lead to a better understanding of the potential impact on the industry and the world at large.
As a responsible and informed member of society, it is essential to stay updated on the latest advancements in healthcare and biotechnology. By following developments in companies like Pyxis Oncology, we can better understand the potential for new treatments and the role biotech plays in improving people’s lives and shaping the future of healthcare.
Stay curious, stay informed.
